A Concise Synthesis of the Pentacyclic Framework of Cortistatins

Shuji Yamashita,*,† Kentaro Iso,† and Masahiro Hirama*,†,‡

Department of Chemistry, Graduate School of Science, Tohoku University, and Research and Analytical Center for Giant Molecules, Graduate School of Science, Tohoku University, Sendai 980-8578, Japan

s-yamashita@mail.tains.tohoku.ac.jp; hirama@mail.tains.tohoku.ac.jp

Received May 28, 2008

ORGANIC LETTERS 2008 Vol. 10, No. 16 3413-3415

ABSTRACT



An efficient synthesis of the pentacyclic framework of cortistatins has been developed. The key strategy comprises assembly of the A- and the CD-ring fragments by Knoevenagel reaction, facile formation of the pyran ring via electrocyclization, and construction of the sevenmembered B-ring by radical addition to an α , β -unsaturated ketone.

Cortistatins, which are unique *abeo*-9(10,19)-androstane-type steroidal alkaloids, were first isolated from the marine sponge *Corticium simplex* by Kobayashi et al.¹ Cortistatin A (1), the most potent congener, was found to inhibit the proliferation of human umbilical vein endothelial cells with extreme selectivity among cell lines.^{1a,2} Because angiogenesis in solid tumors involves proliferation of endothelial cells, **1** has high potential as a selective antitumor agent. As represented by Baran's excellent synthesis from prednisone,³ the biological activity and unique structure-including an oxabicyclo[3.2.1]octene moiety as well as an isoquinoline substituent-of **1** attracts synthetic chemists. Herein, we report a stereoselective synthesis of the ABCD-ring framework of cortistatins.

As illustrated in Scheme 1, we envisioned the construction of 1 via the key intermediate 2 after functionalization of the A-ring and introduction of the isoquinoline unit to the D-ring.

The pentacyclic **2** would be formed through an electrocyclic reaction of dienone **3** followed by radical cyclization. Knoevenagel reaction between diketone **4** and α , β -unsaturated aldehyde **5** was expected to produce the conjugated dienone **3**.

First, the requisite CD-ring moiety was prepared from commercially available (+)-Hajos-Parrish ketone **6** (Scheme 2).⁴ Chemo- and stereoselective reduction of **6** with NaBH₄ in MeOH at low temperature and subsequent TBS protection of the resulting secondary alcohol produced silyl ether **7** in

[†] Department of Chemistry.

^{*} Research and Analytical Center for Giant Molecules.

^{(1) (}a) Aoki, S.; Watanabe, Y.; Sanagawa, M.; Setiawan, A.; Kotoku, N.; Kobayashi, M. J. Am. Chem. Soc. **2006**, 128, 3148. (b) Watanabe, Y.; Aoki, S.; Tanabe, D.; Setiawan, A.; Kobayashi, M. Tetrahedron **2007**, 63, 4074. (c) Aoki, S.; Watanabe, Y.; Tanabe, D.; Setiawan, A.; Arai, M.; Kobayashi, M. Tetrahedron Lett. **2007**, 48, 4485.

⁽²⁾ SAR studies of cortistatins: Aoki, S.; Watanabe, Y.; Tanabe, D.; Arai, M.; Suna, H.; Miyamoto, K.; Tsujibo, H.; Tsujikawa, K.; Yamamoto, H.; Kobayashi, M *Bioorg. Med. Chem.* **2007**, *15*, 6758.

⁽³⁾ Shenvi, R. A.; Guerrero, C. A.; Shi, J.; Li, C.-C.; Baran, P. S. J. Am. Chem. Soc. 2008, 130, 7241.



quantitative yield.⁵ *C*-alkylation of **7** at the C8-position with iodide **8** was accomplished under Molander's conditions (NaH, DMSO in THF)⁶ to give indanone **9** in 53% yield; this was stereoselectively reduced by NiCl₂·6H₂O and NaBH₄ to give the desired *trans*-fused ketone **10**.^{6a,7} The stereo-chemistry of **10** was verified by NOESY experiments (see Supporting Information). Other reductive conditions (H₂, Pd/C; *t*-BuCuH; or Birch reduction)⁸ did not give **10** as a major product.

Regioselective TMS-enol ether formation from **10** followed by oxidation under Saegusa conditions⁹ furnished the C11,12 double bond. Treatment of enone **11** with lithium diisopropylamide and triflic anhydride resulted in the formation of dienyl triflate **12**, which underwent Pd-catalyzed methoxycarbonylation to give methyl ester **13**.¹⁰ Finally, DIBAL reduction and subsequent Dess-Martin oxidation¹¹

(5) (a) Micheli, R. A.; Hajos, Z. G.; Cohen, N.; Parrish, D. R.; Portland,
L. A.; Sciamanna, W.; Scott, M. A.; Wehrli, P. A. J. Org. Chem. 1975, 40,
675. (b) Gardner, J. N.; Anderson, B. A.; Oliveto, E. P. J. Org. Chem. 1969, 34, 107.

provided the α , β -unsaturated aldehyde 14 in 73% overall yield from 11.

With the requisite aldehyde **14** in hand, construction of the oxabicyclo[3.2.1]octene B-ring was pursued (Scheme 3).





Treatment of **14** with cyclohexane-1,3-dione (**4**) (1.5 equiv) in the presence of piperidine (1.1 equiv) in EtOAc (15 mM) for 6 h produced the desired pyran **16** along with its C8-epimer as a 5:1 mixture in one pot (87% combined yield). Knoevenagel reaction between **14** and **4** gave the condensed product **15**, which underwent spontaneous electrocyclization to give **16** as a major product.¹² Selective TBS removal of the primary alcohol, without affecting the secondary one, using HF•pyridine gave **17**, which was treated with I₂, Ph₃P, and imidazole¹³ to afford iodide **18** in 87% overall yield (10:1 diastereomeric mixture). Interestingly, when **18** was kept at -30 °C for 12 h, it crystallized, and the **18**/C8-epimer ratio increased to 20:1, as confirmed by NMR in CDCl₃. However, the ratio changed to 7:1 when the mixture was kept for 1 h in CDCl₃, and then became 5:1 after 7 h at room temperature.

⁽⁴⁾ Hajos, Z. G.; Parrish, D. R. J. Org. Chem. 1974, 39, 1615.

^{(6) (}a) Molander, G. A.; Quirmbach, M. S.; Silva, L. F.; Spenver, K. C., Jr.; Balsells, J. *Org. Lett.* **2001**, *3*, 2257. (b) Hajos, Z. G.; Parrish, D. R.; Oliveto, E. P. *Tetrahedron* **1968**, *24*, 2039.

⁽⁷⁾ For a general review, see: (a) Ganem, B.; Osby, J. O. *Chem. Rev.* **1986**, *86*, 763. (b) Shigehisa, H.; Mizutani, T.; Tosaki, S.; Ohshima, T.; Shibasaki, M. *Tetrahedron* **2005**, *61*, 5057.

⁽⁸⁾ For a review, see: (a) Jankowski, P.; Marczak, S.; Wicha, J. Tetrahedron 1998, 54, 12071.

⁽⁹⁾ Ito, Y.; Hirao, T.; Saegusa, T. J. Org. Chem. 1978, 43, 1011.

⁽¹⁰⁾ Cacchi, S.; Morera, E.; Ortar, G. Tetrahedron Lett. 1985, 26, 1109.

⁽¹¹⁾ Dess, D. B.; Martin, J. C. J. Org. Chem. 1983, 48, 4155.

⁽¹²⁾ For a recent review for constructing 1-oxadecalin, see: Tang, Y.; Oppenheimer, J.; Song, Z.; You, L.; Zhang, X.; Hsung, R. P. *Tetrahedron* **2006**, *62*, 10785.

⁽¹³⁾ Garegg, P. J.; Samuelsson, B. J. Chem. Soc., Chem. Commun. 1979, 978.

These results clearly indicate that **18** equilibrates with the C8-epimer via retrocyclization to the corresponding dienone in solution.

Finally, formation of the seven-membered B-ring was achieved by radical cyclization. After a considerable number of experiments, it was found that treatment of **18** with Et_3B and (TMS)₃SiH furnished the most stable conjugated dienone (**19**) in 78% yield as the sole product.¹⁴ The structure of **19**, the key intermediate in the total synthesis of cortistatins, was unambiguously confirmed by X-ray crystallographic analysis of the corresponding *p*-bromobenzoate **20**.

In conclusion, we have developed a concise and stereocontrolled synthetic route to the pentacyclic framework of cortistatins. The key intermediate **19** was prepared in only 14 steps from the commercially available **6**, including (1) Knoevenagel condensation, (2) spontaneous electrocyclization $(14\rightarrow 16)$, and (3) highly chemoselective internal radical addition $(18\rightarrow 19)$. The strategy developed here will contribute toward the total synthesis of cortistatins, which is being actively investigated in our laboratory.

Acknowledgment. This work was supported financially by a Grant-in-Aid for Scientific Research from Ministry of Education, Culture, Sports, Science and Technology in Japan. We are grateful to Dr. E. Kwon at the Research and Analytical Center for Giant Molecules for his assistance with X-ray crystallographic analysis and helpful discussions.

Supporting Information Available: Experimental procedures and spectroscopic data for synthetic compounds. This material is available free of charge via the Internet at http://pubs.acs.org.

OL8012099

⁽¹⁴⁾ For selected examples of radical addition to α,β -unsaturated carbonyl compounds, see: (a) Middleton, D. S.; Simpkins, N. S. *Tetrahedron* **1990**, *46*, 545. (b) Lee, E.; Tae, J. S.; Lee, C.; Park, C. M. *Tetrahedron Lett.* **1993**, *34*, 4831.